ERCC2 and urothelial carcinoma: However, with the completion of the TCGA sequencing efforts in MIBC[19] and a subsequent exome level sequencing in a NAC MIBC cohort[20], we anticipate that somatic mutations (such as ERCC2, ATM, RB1, FANCC, and others) in urothelial carcinoma will likely also play a role in identifying patients likely to derive benefit from platinum based NAC in MIBC[21,22].